ARID5B and cancer: The AT-rich interaction domain (ARID) family is a superfamily belonging to switch/sucrose nonfermenting (SWI/SNF) chromatin remodeling complexes and the presence of inactivating mutations in any of their members, including ARID5B, has been associated with greater benefit from ICI therapy in pan-cancer analyses [22].